LLY logo

ELI LILLY & CO

LLYNYSE
πŸ† #11 by market capEarnings Feb 2 Β· PreUS Equity
$1,347.11β–Ό $4.05 (βˆ’0.30%)
Market closed Β· at close
πŸ””
Track LLY
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.3%
7dβ–Ό 6.8%
14dβ–Ό 0.6%
30dβ–² 5.7%
ytdβ–² 25.3%
1yβ–² 27.2%
🏦Market Cap
$1.27T
Mega Cap
πŸ“ˆRevenue Growth (YoY)
45.5%
High Growth
πŸ“ŠGross Margin
83.6%
High
πŸ’΅FCF Margin
13.5%
Healthy
βš–οΈP/S Ratio
14.7x
Expensive
Otter Score
80
Strong

Trading Snapshot

Day Range
$1341.88 – $1372.05
52-Week Range
$850.51 – $1,475.25
Volume (shares)
3,540,083
Avg Volume (shares)
β€”
Shares Outstanding
940.8M
Next Earnings
2027-02-02

Fundamentals Snapshot

Annual Revenue
$65.18B
Last Q Revenue
$24.40B
P/E Ratio
46.1
P/S Ratio
14.7x
EPS (TTM)
$30.81
Dividend Yield
0.47%
Dilution (1yr)
βˆ’0.6%
LLY logo

ELI LILLY & CO

LLY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$65.2Bβ–² +44.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
83.0%β–² +2.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$29.7Bβ–² +74.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$9.0Bβ–² +138.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
898.0Mβ–Ό βˆ’0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$35.3Bβ–Ό βˆ’$5.0B YoY
StockOtter Β· stockotter.space

About ELI LILLY & CO

Pharma with leading GLP-1 franchise (Mounjaro, Zepbound).

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100

Analyst Ratings

β“˜
Consensus
Buy
37 analysts
Strong Buy11
Buy21
Hold4
Sell1
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

The Motley FoolΒ·6h ago

Eli Lilly's Obesity Pipeline Is Getting Crowded. That's Great News for Investors

Zepbound and Foundayo currently anchor Eli Lilly's obesity lead. Retatrutide and EloraTZP outperformed Zepbound in weight-loss trials, though not yet in head-to-head Phase 3 studies.

The Motley FoolΒ·15h ago

$1,000 Invested in Eli Lilly 5 Years Ago Is Now Worth Over $5,000. Could It Soar That Much Again by 2031?

Eli Lilly has seen revenue explode higher in recent years thanks to its dominance in the weight loss drug market. Its weight loss portfolio drove double-digit revenue growth in the recent quarter.

The Motley FoolΒ·1d ago

Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight

Zepbound helped adolescents lose substantial weight and improve key health measures in a clinical trial. Younger patients could open a meaningful new market for Eli Lilly's obesity franchise.

Seeking AlphaΒ·2d ago

My Top Dividend Growth Picks In Each GICS Sector (November 2026)

I present my top dividend growth picks in each GICS sector based on quality scores. The sector winners would have returned 144% over five years, versus SPY's 63%. Royal Gold is my standout value candidate. It meets all m

Zacks Investment ResearchΒ·2d ago

Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?

Lilly and Pfizer offer contrasting growth stories driven by blockbuster drugs, expanding pipelines and strategic investments.

The Motley FoolΒ·2d ago

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?

AbbVie generates significant cash flow from its newer immunology stars, Skyrizi and Rinvoq. Eli Lilly is seeing explosive revenue growth driven by its dominant presence in the metabolic health market.